The DOI matches its Crossref record.
A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P)
Open accessAbstract
Vascular-disrupting strategies impair a tumor's blood vessel network, which is essential for tumor progression and metastasis. Vascular-disrupting agents (VDAs) cause a rapid and selective vascular shutdown in tumors to produce extensive secondary neoplastic cell death due to ischemia. A lead agent in this therapeutic strategy is the tubulin depolymerizing agent combretastatin-A4 phosphate (CA4P). Used alone, CA4P induces extensive necrosis in a wide variety of preclinical cancer models and significant blood flow reductions in the patient tumors. Preclinical and clinical data further indicate that CA4P can effectively be combined with chemotherapy or radiotherapy. Finally, the potential of combining VDAs with antiangiogenic therapies has shown considerable promise in preclinical models and such combinations are now beginning to be evaluated in patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Siemann, D. W. (2011) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2010.05.001 · Cited by 611
Self-citationTargeting Microtubules by Natural Agents for Cancer Therapy
Mukhtar, E., Adhami, V. M., & Mukhtar, H. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0791 · Cited by 565
Colchicine-Binding Site Inhibitors from Chemistry to Clinic: A Review
McLoughlin, E. C., & O’Boyle, N. M. (2020) · Pharmaceuticals · doi:10.3390/ph13010008 · Cited by 316
Messaoudi, S., Tréguier, B., Hamze, A., Provot, O., Peyrat, J.-F., De Losada, J. R., Liu, J.-M., Bignon, J., Wdzieczak-Bakala, J., Thoret, S., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900321u · Cited by 287
Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans
Breitbach, C. J., Arulanandam, R., De Silva, N., Thorne, S. H., Patt, R., Daneshmand, M., Moon, A., Ilkow, C., Burke, J., Hwang, T.-H., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2687 · Cited by 258
Metadata
- Authors
- Siemann, D. W., Chaplin, D. J., & Walicke, P. A.
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa UK Limited
- Published
- 2009-01-21
- Volume
- 18
- Issue
- 2
- Pages
- 189-197
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W2143591410
- Cited by
- 250
- References
- 0
- FWCI
- 11.64
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P). https://app.cochat.ai/papers/10.1517/13543780802691068
- The paper
- Siemann, D. W., Chaplin, D. J., & Walicke, P. A. (2009). A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P). Expert Opinion on Investigational Drugs. https://doi.org/10.1517/13543780802691068
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.